173 related articles for article (PubMed ID: 2984249)
41. Synthesis and antiviral properties of (Z)-5-(2-bromovinyl)-2'-deoxyuridine.
Jones AS; Rahim SG; Walker RT; De Clercq E
J Med Chem; 1981 Jun; 24(6):759-60. PubMed ID: 6265638
[TBL] [Abstract][Full Text] [Related]
42. Apoptosis induced by (E)-5-(2-bromovinyl)-2'-deoxyuridine in varicella zoster virus thymidine kinase-expressing cells is driven by activation of c-Jun/activator protein-1 and Fas ligand/caspase-8.
Tomicic MT; Friedrichs C; Christmann M; Wutzler P; Thust R; Kaina B
Mol Pharmacol; 2003 Feb; 63(2):439-49. PubMed ID: 12527816
[TBL] [Abstract][Full Text] [Related]
43. Methotrexate potentiates anti-herpes simplex virus type 1 activity of E-5-(2-bromovinyl)-2'-deoxyuridine.
Pancheva SN
Acta Virol; 1995 Apr; 39(2):117-9. PubMed ID: 7676937
[TBL] [Abstract][Full Text] [Related]
44. Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
Griengl H; Hayden W; Penn G; De Clercq E; Rosenwirth B
J Med Chem; 1988 Sep; 31(9):1831-9. PubMed ID: 2842506
[TBL] [Abstract][Full Text] [Related]
45. The antiherpes drug (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdU) interferes with formation of N-linked and of O-linked oligosaccharides of the herpes simplex virus type 1 glycoprotein C.
Olofsson S; Lundström M; Datema R
Virology; 1985 Nov; 147(1):201-5. PubMed ID: 2998063
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of (E)-5-(2-bromovinyl)-2'-deoxyuridine in the treatment of experimental herpes simplex virus encephalitis in mice.
Park NH; Pavan-Langston D; de Clercq E
Antiviral Res; 1983 Mar; 3(1):7-15. PubMed ID: 6870230
[TBL] [Abstract][Full Text] [Related]
47. Prolonged herpes simplex virus latency in vitro after treatment of infected cells with acyclovir and human leukocyte interferon.
Scheck AC; Wigdahl B; De Clercq E; Rapp F
Antimicrob Agents Chemother; 1986 Apr; 29(4):589-93. PubMed ID: 3010847
[TBL] [Abstract][Full Text] [Related]
48. Characterization and susceptibility to antiviral agents of herpes simplex virus type 1 containing a unique thymidine kinase gene with an amber codon between the first and the second initiation codons.
Saijo M; Suzutani T; Mizuta K; Kurane I; Morikawa S
Arch Virol; 2008; 153(2):303-14. PubMed ID: 18066636
[TBL] [Abstract][Full Text] [Related]
49. Differential binding affinities of sugar-modified derivatives of (E)-5-(2-bromovinyl)-2'-deoxyuridine for herpes simplex virus-induced and human cellular deoxythymidine kinases.
Zou FC; Dutschman GE; De Clercq E; Cheng YC
Biochem Pharmacol; 1984 Jun; 33(11):1797-800. PubMed ID: 6329218
[TBL] [Abstract][Full Text] [Related]
50. Antiviral activity of the 3'-amino derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
De Clercq E; Descamps J; Balzarini J; Fukui T; Allaudeen HS
Biochem J; 1983 May; 211(2):439-45. PubMed ID: 6307280
[TBL] [Abstract][Full Text] [Related]
51. Selective antiherpetic activity of carbocyclic analogues of (E)-5-(2-halogenovinyl)-2'-deoxyuridines: dependence on specific phosphorylation by viral thymidine kinase.
De Clercq E; Balzarini J; Bernaerts R; Herdewijn P; Verbruggen A
Biochem Biophys Res Commun; 1985 Jan; 126(1):397-403. PubMed ID: 2982373
[TBL] [Abstract][Full Text] [Related]
52. (E)-5-(2-bromovinyl)uridine requires phosphorylation by the herpes simplex virus (type 1)-induced thymidine kinase to express its antiviral activity.
Bernaerts R; Desgranges C; De Clercq E
Biochem Pharmacol; 1989 Jun; 38(12):1955-61. PubMed ID: 2545207
[TBL] [Abstract][Full Text] [Related]
53. Antiherpes activity of 5-(2-bromoethyl)-2'-deoxyuridine.
La Colla P; Gelli G; Mura L; Landini MP; Corrias MV; Pani A; Marongiu ME
Antiviral Res; 1985; Suppl 1():29-34. PubMed ID: 3002262
[No Abstract] [Full Text] [Related]
54. Low levels of herpes simplex virus thymidine- thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model.
Coen DM; Irmiere AF; Jacobson JG; Kerns KM
Virology; 1989 Feb; 168(2):221-31. PubMed ID: 2536980
[TBL] [Abstract][Full Text] [Related]
55. Comparison of a DNA probe assay with the plaque reduction assay for measuring the sensitivity of herpes simplex virus and varicella-zoster virus to penciclovir and acyclovir.
Standring-Cox R; Bacon TH; Howard BA
J Virol Methods; 1996 Jan; 56(1):3-11. PubMed ID: 8690764
[TBL] [Abstract][Full Text] [Related]
56. Properties of purified enzymes induced by pathogenic drug-resistant mutants of herpes simplex virus. Evidence for virus variants expressing normal DNA polymerase and altered thymidine kinase.
Larder BA; Derse D; Cheng YC; Darby G
J Biol Chem; 1983 Feb; 258(3):2027-33. PubMed ID: 6296119
[TBL] [Abstract][Full Text] [Related]
57. 5-Iodo-2'-deoxy-L-uridine and (E)-5-(2-bromovinyl)-2'-deoxy-L-uridine: selective phosphorylation by herpes simplex virus type 1 thymidine kinase, antiherpetic activity, and cytotoxicity studies.
Spadari S; Ciarrocchi G; Focher F; Verri A; Maga G; Arcamone F; Iafrate E; Manzini S; Garbesi A; Tondelli L
Mol Pharmacol; 1995 Jun; 47(6):1231-8. PubMed ID: 7603465
[TBL] [Abstract][Full Text] [Related]
58. Resistance of herpes simplex virus to adenine arabinoside and E-5-(2-bromovinyl)-2'-deoxyuridine: a physical analysis.
Crumpacker CS; Schnipper LE; Kowalsky PN; Sherman DM
J Infect Dis; 1982 Aug; 146(2):167-72. PubMed ID: 6286786
[TBL] [Abstract][Full Text] [Related]
59. Antiviral activity of cyclosaligenyl prodrugs of the nucleoside analogue bromovinyldeoxyuridine against herpes viruses.
Meerbach A; Meier C; Sauerbrei A; Meckel HM; Wutzler P
Int J Antimicrob Agents; 2006 May; 27(5):423-30. PubMed ID: 16621459
[TBL] [Abstract][Full Text] [Related]
60. Comparative activity of various compounds against clinical strains of herpes simplex virus.
Andrei G; Snoeck R; Goubau P; Desmyter J; De Clercq E
Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):143-51. PubMed ID: 1327785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
